Key result
Intravenous c-kit-positive cardiac cells improve LVEF by ~9 percentage points over vehicle in post-MI rats.
Why the study?
Direct transendocardial cell delivery for chronic heart failure is logistically complex, expensive, risky, and not amenable to multiple dosing. Whether convenient intravenous infusion of three widely used cell types improves left ventricular function and structure in chronic ischemic cardiomyopathy, and how their efficacy compares, was unknown.
Answers are grounded in this paper and cite their sources.
Demonstrates that intravenous cell therapy attenuates left ventricular functional decline in rats with chronic ischemic cardiomyopathy, indicating the viability of systemic delivery.
Mounting evidence shows that cell therapy provides therapeutic benefits in experimental and clinical settings of chronic heart failure. However, direct cardiac delivery of cells via transendocardial injection is logistically complex, expensive, entails risks, and is not amenable to multiple dosing. Intravenous administration would be a more convenient and clinically applicable route for cell therapy. Thus, we determined whether intravenous infusion of three widely used cell types improves left ventricular (LV) function and structure and compared their efficacy. Rats with a 30-day-old myocardial infarction (MI) received intravenous infusion of vehicle (PBS) or 1 of 3 types of cells: bone marrow mesenchymal stromal cells (MSCs), cardiac mesenchymal cells (CMCs), and c-kit-positive cardiac cells (CPCs), at a dose of 12x106 cells. Rats were followed for 35 days after treatment to determine LV functional status by serial echocardiography and hemodynamic studies. Blood samples were collected for Hemavet analysis to determine inflammatory cell profile. LV ejection fraction (EF) dropped ≥20 points in all hearts at 30-day after MI and deteriorated further at 35-day follow-up in the vehicle-treated group. In contrast, deterioration of EF was halted in rats that received MSCs and attenuated in those that received CMCs or CPCs. None of the 3 types of cells significantly altered scar size, myocardial content of collagen or CD45-positive cells, or Hemavet profile. This study demonstrates that a single intravenous administration of 3 types of cells in rats with chronic ischemic cardiomyopathy is effective in attenuating the progressive deterioration in LV function. The extent of LV functional improvement was greatest with CPCs, intermediate with CMCs, and least with MSCs.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2021) studied Chronic ischemic cardiomyopathy (30-day-old reperfused myocardial infarction) (n=48). Intravenous cell therapy: c-kit-positive cardiac cells (CPCs), cardiac mesenchymal cells (CMCs), or bone marrow mesenchymal stromal cells (MSCs) vs. Vehicle (5 ml Dulbecco's phosphate-buffered saline) was evaluated on Change in left ventricular ejection fraction (LVEF, %) at 35 days post-treatment (CPC group vs. vehicle) (p=<0.01). Intravenous c-kit-positive cardiac cells improved LVEF by +6.51%, outperforming cardiac mesenchymal and bone marrow stromal cells in rats with old MI.
Synapse has enriched 10 related papers. Consider them for comparative context: